We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Global X China Biotech Innovations ETF | NASDAQ:CHB | NASDAQ | Exchange Traded Fund |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 6.64 | 2.67 | 10.66 | 0 | 00:00:00 |
RNS Number:7622N Merrill Lynch Investment ManagersLd 21 July 2003 FORM 8.1/8.3 Lodge with Company Announcements Office (which will publicise and copy to the Panel). Use separate form for each class of securities in which dealings have been made. Date of disclosure: 21st July, 2003 DISCLOSURE UNDER RULES 8.1(a), 8.1(b)(i) AND 8.3 OF THE CITY CODE ON TAKE-OVERS AND MERGERS Date of dealing: 17th July, 2003 Dealing in: Chubb plc (Name of Company) (1) Class of securities: 36p Ordinary Shares (eg ordinary shares): (2) Amount bought Amount sold Price per unit 739,301 75.75p (3) Resultant total of the same class owned or controlled (and percentage of class 59,906,581 (7.22%) (4) Party making disclosure : MERRILL LYNCH INVESTMENT MANAGERS LIMITED (5) EITHER (a) Name of purchaser/vendor (note 1) OR (b) If dealing for discretionary client(s), name of fund management organisation: MERRILL LYNCH INVESTMENT MANAGERS LIMITED (6) Reason for disclosure (Note 2) (a) associate of (i) offeror (Note 3) XXX/NO (ii) offeree company YES/XX Specify which category or categories of associate (1-8 overleaf) If category (8), explain ...Category 6....................................... (b) Rule 8.3 (ie disclosure because of ownership or control of 1% or more of the class of relevant securities dealt in) YES/XX Signed, for and on behalf of the party named in (4) above (Also print name of signatory): Keli Walters Telephone and extension number 020 7964 7492 Note 1. Specify owner, not nominee or vehicle company. If relevant, also identify controller of owner, eg where an owner normally acts on instructions of a controller. Note 2. Disclosure might be made for more than one reason: if so, state all reasons. Note 3. Specify which offeror if there is more than one. Note 4. When an arrangement exists with any offeror, with the offeree company or with an associate of any offeror or of the offeree company in relation to relevant securities, details of such arrangement must be disclosed, as required by Note 6 on Rule 8. ........................................................................................ This information is provided by RNS The company news service from the London Stock Exchange END DCCPUUGGMUPWGGG
1 Year Global X China Biotech I... Chart |
1 Month Global X China Biotech I... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions